Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

In conclusion, DAC in combination with the FC lymphod epletion regimen may be a new treatment option that can improve the efficacy of CAR T-cell therapy in r/r B-ALL.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research